Compare Amphastar Pharmaceuticals Inc (AMPH) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Micron Technology, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Micron Technology, Inc. trades at $866.27 (market cap $972.41B). The key difference: Micron Technology, Inc. is far larger — about 1125.5× Amphastar Pharmaceuticals Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MU | |
|---|---|---|
Market Cap | $863.95M | $972.41B |
Sector | Health | Technology |
52-Week High | $30.81 | $1.21K |
52-Week Low | $16.87 | $115.79 |
Enterprise Value | $1.26B | $952.76B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Micron Technology (MU) trades at $877.57, down 0.44% on the day, with technical indicators showing a neutral overall signal and bullish moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $25.11 versus $20.98 expected, driven by robust AI memory demand. Revenue surged to $37.38 billion in 2025, with net income margin at 55.91%. Analyst consensus is overwhelmingly bullish with an 81.43% buy rating and a $1,540 price target.
Outlook remains positive due to structural demand for high-bandwidth memory in AI, but risks include cyclical pricing pressures and competitive capacity expansions. The stock offers growth potential amid tight supply conditions, though volatility from valuation concerns and macroeconomic factors persists. Key support sits at $848 with resistance at $906.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
